. The most common type of liver disease, non alcoholic fatty liver disease (NAFLD), affects >65 million Americans with a cost burden of US$103 billion annu ally within the USA 3 . To manage the socioeconomic burden of gastrointestinal associated liver diseases by developing new therapeutic modalities, specific molecu lar events that facilitate interaction between the gut and the liver must be elucidated. As we begin to appreciate these links, animal models [4] [5] [6] and well designed clini cal studies [7] [8] [9] are already revealing key components of these interactions.
The present understanding of the aetiology of the spectrum of liver diseases (Fig. 1) is underpinned by pro inflammatory changes in the host. Intestinal dysbiosis (anomalous or imbalanced gut microbial composition) and increased intestinal permeability lead to translocation of microorganisms and microbial products, including cell wall components (endotoxins from Gram negative bacte ria and β glucan from fungi) and DNA, together referred to as microbial associated mole cular patterns (MAMPs) or pathogen associated molecular patterns (PAMPs). These patterns are recognized by immune receptors on liver cells (such as Kupffer cells and hepatic stellate cells) and intestinal lamina propria (an immune cellrich tis sue beneath the intestinal epithelium), which initiate and maintain inflammatory cascades that ultimately lead to liver damage in the form of fibrosis [10] [11] [12] [13] . This damage can progress from cirrhosis (severe fibrosis) to hepatocellular carcinoma (HCC), the most predominant form (>80%) of primary liver cancer 14 . Previously demonstrated associa tions between intestinal health and several different types of neoplasia suggest a potential role of the microbiota in HCC 15, 16 . Additionally, the liver and microbiota engage in co metabolism of xenobiotics, including carcinogens (such as diet derived 2amino3methylimidazo [4,5f] quinoline), which can independently predispose the host to HCC 17, 18 . The missing links in the complex interaction network between host and microorganisms are being discov ered piece by piece using various experimental designs (detailed later). These findings encourage microbiome oriented therapeutic modalities to treat liver associated and other metabolic diseases. Here, we review the cur rent understanding of the aetiology of liver diseases and highlight the open research questions ( 4, 8 , Bernd Schnabl 6, 7, 8 and Rob Knight 2, 5, 8 * Abstract | In the past decade, an exciting realization has been that diverse liver diseases -ranging from nonalcoholic steatohepatitis, alcoholic steatohepatitis and cirrhosis to hepatocellular carcinoma -fall along a spectrum. Work on the biology of the gut-liver axis has assisted in understanding the basic biology of both alcoholic fatty liver disease and nonalcoholic fatty liver disease (NAFLD). Of immense importance is the advancement in understanding the role of the microbiome, driven by high-throughput DNA sequencing and improved computational techniques that enable the complexity of the microbiome to be interrogated, together with improved experimental designs. Here, we review gut-liver communications in liver disease, exploring the molecular, genetic and microbiome relationships and discussing prospects for exploiting the microbiome to determine liver disease stage and to predict the effects of pharmaceutical, dietary and other interventions at a population and individual level. Although much work remains to be done in understanding the relationship between the microbiome and liver disease, rapid progress towards clinical applications is being made, especially in study designs that complement human intervention studies with mechanistic work in mice that have been humanized in multiple respects, including the genetic, immunological and microbiome characteristics of individual patients. These 'avatar mice' could be especially useful for guiding new microbiome-based or microbiome-informed therapies.
*e-mail: robknight@ ucsd.edu focused research in this area with special attention to the role of the microbiome.
How do the liver and gut communicate?
The gut and liver communicate via tight bidirectional links through the biliary tract, portal vein and systemic circulation (Fig. 2) . The liver communicates with the intes tine by releasing bile acids and many bioactive mediators into the biliary tract and the systemic circulation. In the intestine, host and microorganisms metabolize endoge nous (bile acids and amino acids) as well as exogenous (from diet and environmental exposure) substrates, the products of which translocate to the liver through the portal vein and influence liver functions 19 . Some crucial links between the gut and liver are discussed herein.
Enterohepatic circulation of bile acids
Bile acids (BAs) are amphipathic molecules synthesized from cholesterol in the pericentral hepatocytes. These primary BAs are reconjugated to glycine or taurine and released in the biliary tract. On reaching the small intes tine through the duodenum, BAs, together with other biliary components, facilitate emulsification and absorp tion of dietary fats, cholesterol and fat soluble vitamins. About 95% of the BAs are actively reabsorbed in the terminal ileum and transported back to the liver 20, 21 . The remaining 5% are deconjugated, dehydrogenated and dehydroxylated by the colonic microbiota to form secondary BAs, which reach the liver via passive absorp tion into the portal circulation 22 . The liver recycles BAs and secretes them back to the biliary tract, completing the so called enterohepatic circulation, that is, a system of exchange between the gut and the liver.
A carrier mediated process transports hydrophilic primary BAs across cell membranes for uptake into intestinal epithelial cells. Regulatory effects of BAs have been best studied with respect to farnesoid X receptor (FXR; also known as NR1H4) and G protein coupled bile acid receptor 1 (GPBAR1; also known as TGR5). BAs bind to FXR in the enterocytes and induce transcription of an enterokine, fibroblast growth factor 19 (FGF19; FGF15 in mouse) 23 . FGF19 reaches the liver through the portal vein and downregulates de novo BA synthesis by inhibiting cholesterol 7α monooxygenase (CYP7A1) in hepatocytes, forming a feedback system for modulat ing BA production 23 . FXR activation is known to affect glucose and lipid metabolism 24, 25 . Additionally, BAs bind to TGR5 on the plasma membrane and act on tissues beyond enterohepatic circulation. This binding mediates host energy expenditure 26, 27 , glucose homeostasis 28 and anti inflammatory immune responses 29, 30 . BAs and the gut microbiota closely interact and mod ulate each other; BAs exert direct control on the intestinal microbiota. By binding to FXR, they induce production of antimicrobial peptides (AMPs) such as angiogenin 1 and RNase family member 4, which are directly involved in inhibiting gut microbial overgrowth and subsequent gut barrier dysfunction 31, 32 . Intestinal dysbiosis shifts the balance between primary and secondary BAs and their subsequent enterohepatic cycling, the metabolic effects of which are not comprehensively understood. However, because of differences in the affinity of these two classes of BAs for FXR, these shifts have been associated with changes in hepatic bile acid synthesis and metabolic stress 22, [33] [34] [35] . An imbalance in BAs and gut bacteria elicits a cascade of host immune responses relevant to the progression of liver diseases (discussed later).
Intestinal permeability
The central components of the intestinal barrier are enterocytes that are tightly bound to adjacent cells by apical junctional proteins that include claudins, occlu dins, E cadherins, desmosomes and junctional adhesion molecules 36 . This barrier restricts movement of micro organisms and molecules from the gut lumen while allowing permselective, active transport of nutrients across the tight junctions. The intestinal barrier is fur ther strengthened by several additional lines of defence. Mucins (heavily glycosylated protein aggregates) form a physical barrier between luminal bacteria and the underlying epithelial layer 37 , and antibacterial lectins, such as regenerating islet derived protein IIIγ (REG3G), are produced by intestinal Paneth cells to target bacteria associated with mucosal lining 38, 39 . Moreover, immuno globulins (specifically secretory immunoglobulin A (IgA)) produced by plasma cells and transported into the lumen through the intestinal epithelial cells neutral ize microbial pathogens by blockading epithelial recep tors 40 . Finally, commensal bacteria are closely associated with the gut mucosa and reinforce barrier integrity
Key points
• The liver and intestine communicate extensively through the biliary tract, portal vein and systemic mediators.
• liver products primarily influence the gut microbiota composition and gut barrier integrity, whereas intestinal factors regulate bile acid synthesis, glucose and lipid metabolism in the liver.
• Diverse liver diseases (including nonalcoholic fatty liver disease and alcoholic liver disease) are not unrelated but converge along a common path of progression; pro-inflammatory changes in the liver and intestine mediate development of fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma.
• Alcoholic and nonalcoholic fatty liver diseases share key characteristics, such as intestinal dysbiosis, gut permeability and shifts in levels of bile acids, ethanol and choline metabolites.
• Precise contributions of the microbiome to liver diseases could differ based on aetiology; improvements in experimental design and development of animal models are rapidly elucidating causal mechanisms.
• Advances in understanding the gut-liver axis could encourage research into microbiome-based, diagnostic, prognostic and therapeutic modalities to improve management of liver diseases.
by stimulating cell mediated immunity via Toll like receptor (TLR)mediated signalling 38, 41 or by produ cing metabolites that directly strengthen tight junctions (short chain fatty acids (SCFAs)) [42] [43] [44] and inhibit other microorganisms [45] [46] [47] . Breakdown of one or more of these barrier com ponents compromises gut barrier integrity. The major drivers of increased permeability include gut inflam mation and dysbiosis 48, 49 , which have been linked to consumption of a high fat Western diet [50] [51] [52] , chronic alcohol consumption [53] [54] [55] , prolonged antibiotic usage 56 and immune mediated inflammatory diseases such as IBD 57 . An important association between the gut microbiota, inflammation and gut barrier integrity is provided by Akkermansia muciniphila, a Gram negative anaerobe that colonizes the intestinal mucous layer. Reduced abundance of A. muciniphila has been asso ciated with thinning of the mucous layer (compromis ing gut barrier integrity) and increased inflammation, which promote both alcoholic and nonalcoholic liver damage 58, 59 . When the gut barrier is compromised, microorganisms and microorganism derived molecules can translocate to the liver through the portal system, causing inflammation and hepatic injury 13 . Some trans located intestinal products might also directly interact with host factors and contribute to exacerbation of liver disease [60] [61] [62] [63] [64] [65] (Fig. 3) .
Systemic circulation
Bacteria and MAMPs. Intestinal permeability is charac terized by compromised tight junctions between entero cytes and is consistently seen across the spectrum of liver diseases 66, 67 . Liver damage is associated with small intes tinal bacterial overgrowth (SIBO) and dysbiosis of the lower gastrointestinal tract 68 . Together, these processes lead to increased translocation of MAMPs into the por tal circulation. On reaching the liver, MAMPs induce localized inflammation through pattern recognition receptors (PRRs) on Kupffer cells 69 and hepatic stel late cells 70, 71 . Endotoxin mediated activation of TLR4
(reFS 69, 70 ), TLR9 (activated by methylated DNA) 71 and TLR2 (activated by Gram positive bacteria) 72 are the pri mary drivers of immune response in liver disease. TLR signalling in Kupffer cells activates a downstream pro inflammatory cascade, leading to myeloid differentiation primary response protein (MYD88)mediated activation of nuclear factor κB (NF κB) 13 . Additionally, TLR4 sig nalling also promotes fibrosis by downregulating BMP and activin membrane bound inhibitor homologue (BAMBI) (a decoy receptor for transforming growth factor β (TGFβ)) in hepatic stellate cells 13 . These steps lead to expression of inflammatory cytokines, oxidative and endoplasmic reticulum (ER) stress and subsequent liver damage 73 .
Choline metabolites. Choline is a macronutrient that is important for liver function, brain development, nerve function, muscle movement and for maintaining a healthy metabolism 74 ; notably, rodents fed a choline deficient diet have been used to model human nonalco holic steatohepatitis (NASH) [75] [76] [77] . Choline is processed into phosphatidylcholine (lecithin) by the host, which assists in excretion of VLDL particles from the liver. This process prevents hepatic accumulation of trigly cerides (liver steatosis) 78 . Additionally, choline can also be con verted to trimethylamine (TMA) by intestinal bacteria; TMA can translocate to the liver through the portal circulation where it is converted to trimethylamine N oxide (TMAO) 79 . The importance of methylamines is increasingly being recognized with respect to liver, Risk factors such as alcohol abuse, unbalanced diet, infection (HBV or HCV) or immune dysfunction (primary biliary cholangitis or primary sclerosing cholangitis) can independently lead to liver injury. Individuals who abuse alcohol and individuals with obesity often develop steatosis (fatty liver), which is characterized by increased intestinal permeability and dysbiosis. Subsequently , bile acid and choline homeostasis are disturbed along with increased translocation of microbial-associated molecular patterns (MAMPs) across the gut barrier, leading to steatohepatitis, the progressive form of liver damage. Both steatosis-dependent and steatosis-independent liver damage can progress to cirrhosis (end-stage liver damage), which is marked by translocation of viable bacteria to the liver and severe inflammation. As liver function is progressively compromised, tumour-promoting metabolites and xenobiotics accumulate. These could activate oncogenic pathways causing hepatocellular carcinoma, the most predominant form of primary liver cancers. ALD, alcoholic liver disease; ASH, alcoholic steatohepatitis; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis.
cardiometabolic and, more recently, neurological dis orders 79, 80 . Increased systemic circulation of TMAO is concomitant with reduced levels of host produced phos phatidylcholine, an imbalance characteristically seen in those with intestinal dysbiosis. TMAO has been linked with liver damage owing to increased triglyceride accu mulation (hepatic steatosis) 9, 79, [81] [82] [83] and, consequently, NAFLD in humans and experimental models 9 .
Free fatty acids. Free fatty acids include SCFAs and long chain fatty acids (LCFAs). Butyrate, propionate (pro duced by bacterial fermentation) and acetate (produced by both host and bacteria) are the dominant SCFAs in the large intestine. Butyrate is an energy source for the enterocytes and facilitates maintenance of the intestinal barrier [42] [43] [44] . Alcohol induced liver injury is suggested to be marked by reduced levels of butyrate and propion ate 84, 85 and increased levels of acetate (possibly produced by ethanol metabolism in the lumen but predominantly derived from ethanol metabolism in the liver). A reduc tion in butyrate is linked to weakening of intestinal tight junctions and, hence, permeability 85 . Butyrate supple mentation in the form of a glycerol ester, tributyrin, reduced ethanol induced intestinal permeability and subsequent liver injury in mice on a short term alcohol diet 85 . However, how tributyrin mechanistically protects the intestinal barrier remains to be established.
Luminal species of LCFAs include pentadecanoic acid (C15:0), palmitic acid (C16:0), heptadecanoic acid (C17:0) and stearic acid (C18:0). In mice fed alcohol chronically, C15:0 and C17:0, which are only produced by bacterial fermentation, are markedly reduced when compared with control mice on an isocaloric diet 84, 86 . There is also an overall reduction in total saturated LCFA levels, which is associated with decreased luminal abun dance of lactobacilli (known metabolizers of saturated LCFAs) 84 . To our knowledge, restoring Lactobacillus spp. by LCFA supplementation has not been experimentally demonstrated. However, dietary supplementation of Lactobacillus rhamnosus has been shown to increase luminal LCFA levels 86 , suggesting that Lactobacillus induced increase in intestinal FFAs contributes to its probiotic effects [87] [88] [89] [90] [91] [92] [93] .
Ethanol and acetaldehyde. The mucosa of the gastro intestinal tract absorbs ethanol by simple diffusion. Within the gastrointestinal tract, the majority of etha nol from food and beverages is absorbed by the stom ach (~20%) and small intestine (~70%) 94, 95 . Although microbial fermentation contributes to luminal ethanol concentration, the largest share of alcohol in the large intestine comes from the systemic circulation 13 . Gut microbiota and enterocytes express alcohol metabolizing enzymes such as alcohol dehydrogenase, which co metabolizes ethanol into acetaldehyde and, to a lesser studied extent, acetate 96, 97 . The liver also responds to circulating levels of ethanol by upregulat ing its ethanol metabolism pathway 97, 98 . The impor tance of microorganisms for xenobiotic metabolism was underscored by a study that demonstrated an increase in hepatic expression of ethanol metabolizing genes in germ free mice and exacerbation in hepatic steatosis 87 . Nonalcoholic and alcoholic liver disease (ALD) (TaBle 1) are characterized by increased luminal and circulating levels of ethanol and its metabolites, acetal dehyde and acetate 65, 99 . These metabolites have inde pendently been associated with liver damage [62] [63] [64] . Acetaldehyde has been implicated in weakening the intestinal tight junctions, compromising the gut barrier and enabling translocation of microbial products [100] [101] [102] [103] [104] [105] . It has also been associated with downregulating the expres sion of AMPs in the intestine 106, 107 and eliciting inflam matory and adaptive host immune responses [108] [109] [110] . These changes, in addition to reduced intestinal levels of butyrate 84, 111, 112 , weaken intestinal tight junctions and promote permeability 85, [113] [114] [115] .
Microbiome and specific liver disease NAFLD NAFLD refers to a spectrum of liver diseases that can be broadly classified into two categories: nonalcoholic fatty liver, the non progressive form of NAFLD, and NASH, the progressive form of NAFLD 116 . NASH is generally linked to type 2 diabetes mellitus, cardiovascular risk factors and obesity 117, 118 , although NAFLD has also been reported in lean individuals, emphasizing that genetic and environmental factors also contribute to disease development [119] [120] [121] [122] . Several studies have stressed the role of the gut microbiota in NAFLD, but causality is yet to be estab lished 123 . Patients with NAFLD have a higher prevalence of SIBO 66, 124 and microbial dysbiosis 125 . Using 16S ampli con sequencing, Boursier et al. 125 found that the bacterial genera Bacteroides and Ruminococcus were substantially increased, and Prevotella was reduced in patients with NASH (stage 2 fibrosis or higher) compared with those without NASH. Loomba et al. 7 utilized whole genome metagenomics to characterize the gut microbiota in patients with NAFLD with and without advanced fibrosis (stages 3 and 4) and showed an increased abundance of Escherichia coli and Bacteroides vulgatus in patients with advanced fibrosis. An enrichment of Escherichia (genera) Box 1 | Open research questions mounting evidence implicates the gut microbiome in the development and progression of different forms of liver disease. However, several questions remain open and must be answered to advance the field.
• Is there a set of microorganisms (beneficial or harmful) that can read out the current extent, or predict the future extent, of disease progression in patients with alcoholic liver disease and NAFlD? • Can microbiome research using a consistent set of methodologies, including multi-omics profiling, provide a consistent mechanistic picture that unifies our understanding of the relationships among forms of liver disease? • Can faecal microbiota transplantation or collections of probiotic strains isolated from human faeces be expanded as a therapeutic modality for liver disease? • Does introducing a humanized microbiome into a hepatocellular carcinoma avatar mouse improve its fidelity in terms of responding to therapeutic options like an individual patient?
was also seen in paediatric patients with NASH com pared with children with obesity but without NASH 65 . Consistent with preclinical studies, these studies indi cated an association between Gramnegative bacteria and progression of liver fibrosis 126 .
Genetically modified mouse models have been used to study NAFLD associated gut dysbiosis and permeability for mechanistic insights in liver disease progression. Rahman et al. 127 used junctional adhesion molecule A protein (Jam1)knockout mice to demon strate that deficiency in this tight junction protein with a diet rich in saturated fats, fructose and cholesterol leads to increased intestinal permeability and liver inflammation. This inflammation could be alleviated by administering antibiotics, underscoring the impor tance of microbial translocation in promoting immune response in the liver. Another group used mice deficient in Muc2 (predominant mucin in the intestinal mucous layer) and found that there was a compensatory increase in intestinal levels of the antimicrobial protein coding genes Reg3b and Reg3g, leading to an overall protective response against NAFLD 107 . The contribution of liver damaging inflammation in response to translocation of microorganisms and MAMPs has been elucidated 49 . Using inflammasome deficient mouse models (Nlrp3 −/− or Nlrp6 −/− ), Henao Mejia et al. concluded that there was an accumulation of MAMPs in portal circulation, which increased the expression of hepatic TNF, thereby promoting liver inflammation and NASH progression. Furthermore, co housing inflammasome deficient mice with wild type controls exacerbated diet induced hepatic steatosis and obesity in healthy cage mates, suggesting transferability of disease via the microbiota.
Increasing links between NAFLD and the gut micro biome at both the observational and mechanistic levels make the gut microbiota an attractive source of bio markers for early diagnosis of NAFLD. In a comparison between children with obesity with and without NASH, Zhu and colleagues 65 observed markedly elevated gut microbial production of ethanol in those with NASH. Adults with NAFLD also showed increased serum TMAO 9 and hepatic bile acid synthesis 35 and decreased production of phosphatidylcholine 128 . Furthermore, Loomba et al. observed differences in carbon and amino acid metabolism in the gut microbiome of patients with NAFLD associated advanced fibrosis 7 . This proof ofconcept study provides preliminary evidence to sup port the utility of a microbiome derived metagenomics signature to detect advanced fibrosis as well as candidacy for antifibrotic treatment trials in NAFLD.
Alcoholic liver disease
The manifestation of ALD in patients who chronically abuse alcohol is a consequence of multifactorial inter actions involving genetics, the immune system, the gut microbiome and environmental factors 100, [129] [130] [131] . Like NAFLD, the non progressive form of ALD is character ized by accumulation of fat inside the liver (fatty liver or steatosis), whereas the progressive form is marked by inflammation and liver injury (alcoholic steatohepatitis (ASH)).
Our understanding of the compositional and mech anistic contributions of the gut microbiota in ALD is improving. As in NAFLD, SIBO has been demonstrated as an important hallmark of alcohol associated liver disease in humans 35 and mouse models 106, 131 . Intestinal dysbiosis in individuals who abuse alcohol is character ized by marked enrichment of Enterobacteriaceae (fam ily) and reduction in abundance of Bacteroidetes and Lactobacillus (genera) 106, [132] [133] [134] . It has also been demon strated that alcohol induced dysbiosis is only partially reversible by alcohol withdrawal or probiotic (oral supplementation of Lactobacillus plantarum 8PA3 and Bifidobacterium bifidum) treatment 91, 113 . Interestingly, patients dependent on alcohol also displayed reduced fungal diversity and Candida overgrowth, presenting the first evidence of the role of the gut mycobiome in pathogenesis of liver diseases 8 .
Genetically modified murine models have advanced our mechanistic understanding of the contribution of various components of the gut barrier in the aetiology and progression of ALD. Using Reg3b −/− or Reg3g −/− mice, it was found that REG3 lectins protected against alco holic steatohepatitis by reducing mucosa associated microbiota, thereby preventing translocation of via ble bacteria 135 . Muc2deficient mice were protected against alcohol induced liver inflammation (similar to high fatdiet induced inflammation in the NAFLD model) owing to a compensatory increase in Reg3g and Reg3b 107 . Furthermore, IgA knockout in mice led to increased levels of IgM and a net protective effect against ASH progression 136 . Fig. 2 | Bidirectional communication between gut and liver. The liver transports bile salts and antimicrobial molecules (immunoglobulin A (IgA) and angiogenin) to the intestinal lumen through the biliary tract. This process maintains gut eubiosis by controlling unrestricted bacterial overgrowth. Bile salts also act as important signalling molecules via nuclear receptors (such as farnesoid X receptor (FXR) and G proteincoupled bile acid receptor (GPBAR1; also known as TGR5)) to modulate hepatic bile acid synthesis, glucose metabolism, lipid metabolism and energy utilization from diet. Conversely , gut products, such as host and/or microbial metabolites and microbialassociated molecular patterns (MAMPs), translocate to the liver via the portal vein and influence liver functions. Additionally , systemic circulation extends the gut-liver axis by transporting liver metabolites from dietary , endogenous or xenobiotic substances (for example, free fatty acids, choline metabolites and ethanol metabolites) to the intestine through the capillary system. Owing to this medium of transport and ease of diffusion of systemic mediators across blood capillaries, these factors could affect the intestinal barrier positively (for example, butyrate) or negatively (for example, acetaldehyde). TMA , trimethylamine; TMAO, trimethylamine N-oxide.
In response to ethanol induced gut barrier dysfunc tion and translocation, TLRs and other PRRs activate hepatic Kupffer cells and macrophages, as was demon strated in male Wistar rats 137 . This step initiates inflam matory cascades releasing TNF, IL1, IL10, IL12 and TGFβ [138] [139] [140] . Using TLR4 chimaeric mice, it was shown that endotoxin induced release of TGFβ is mediated by a MYD88-NF κBdependent pathway, providing an explanatory mechanism for endotoxin induced liver inflammation 69 . 141, 142 . This increase could be explained by dysbiosis associated disruption in FXR activation in enterocytes as FXR deficient mice were more likely to develop ethanol induced steatohepatitis 143 , and treat ment with an FXR agonist (WAY362450) had protec tive effects against liver damage 144 . Alcohol associated dysbiosis in mice was further linked to reduced LCFA biosynthesis such that LCFA supplementation restored eubiosis. In fact, a statistically significant correlation between Lactobacillus spp. and bacterial LCFA (C15:0 and C17:0) was found in patients with ALD but not in healthy individuals as controls 84 . Butyrate (a SCFA) production was also negatively altered following etha nol exposure and administration of butyrate in the form of tributyrin mitigated alcohol induced liver injury in mice 85 . With increasing evidence of mechanistic links between the gut microbiota and liver disease progres sion, faecal microbiota transplantation (FMT) is being explored as a therapeutic option for ALD 68, 131 . However, larger and carefully designed trials across multiple ethnic groups are needed before FMT can be considered safe in routine clinical practice for managing ALD.
Cirrhosis
Cirrhosis (or end stage liver disease) is an extreme mani festation of chronic liver injury characterized by loss of liver cells, thick fibrous scars and regenerating nodules; this topic has been extensively reviewed elsewhere so we only provide a brief discussion here 145 . NAFLD, ALD, primary biliary cholangitis (PBC; Box 2), primary sclerosing cholangitis (PSC; Box 3) and hepatitis can each progress to cirrhosis and constitute its subtypes. ASH and NASH have emerged as the second and third leading causes of cirrhosis in adults in the USA (after chronic HCV infection) 146 , and based on the aetiology, there is a variable risk of developing HCC [147] [148] [149] . Alterations in the gut microbiota, including dysbio sis and SIBO, have been associated with cirrhosis and its complications [150] [151] [152] [153] . Treatment for portal systemic encephalopathy and decompensated cirrhosis includes treatment with nonsystemic antibiotics, such as rifaximin, Intestinal dysbiosis and bacterial overgrowth are observed in both alcoholic liver disease (ALD) (part a) and nonalcoholic fatty liver disease (NAFLD) (part b). Bacterial overgrowth causes an increase in secondary bile acids (BAs), which modulates farnesoid X receptor (FXR)-mediated hepatic synthesis of BA, leading to an overall increase in hepatic BA synthesis. A reduction in hepatic phosphatidylcholine is also seen in both ALD and NAFLD, which causes triglyceride accumulation in the liver (fatty liver). While ALD-associated dysbiosis is characterized by reduction in Lactobacillus and Candida overgrowth, patients with NAFLD have a higher abundance of Lactobacillus (effects on fungal population remain to be investigated). In ALD and NAFLD, increased ethanol and its metabolite acetaldehyde in the intestinal lumen mediate weakening of intestinal tight junctions. Consequently , increased translocation of microbial-associated molecular patterns (MAMPs) (seen in ALD and NAFLD) and gut metabolites, such as acetaldehyde, acetate (seen in ALD) and trimethylamine (TMA , seen in NAFLD), elicits intestinal and hepatic inflammatory responses, leading to progressive liver damage. AMP, antimicrobial peptides; EtOH, ethanol; HFD, high-fat diet; LCFAs, long-chain fatty acids, TMAO, trimethylamine N-oxide.
to reduce intestinal microbiota overgrowth [154] [155] [156] . Gut microbiome alterations were observed in patients with alcohol associated and hepatitis associated cirrhosis in a Chinese cohort 157 , with an invasion of the lower intes tinal tract by microorganisms associated with the oral cavity, such as Veillonella and Streptococcus. Concordant with these findings, Chen and colleagues also found an overrepresentation of genera, including Veillonella, Megasphaera, Dialister, Atopobium and Prevotella in the duodenum of patients with cirrhosis. The genera Neisseria and Gemella were discriminative between HBV related and PBC related cirrhosis 153 . In 2017, Bajaj and colleagues observed statistically significant fungal dysbiosis in patients with cirrhosis and showed that the Bacteroidetes:Ascomycota ratio could independently predict hospitalization in these patients 158 .
All experimental models of liver fibrosis result in gut microbial dysbiosis and increased intestinal permeability, and treatment of the gastrointestinal tract with nonabsorbable antibiotics (such as rifax imin and neomycin) improved survival by immuno modulation, reducing translocation and incidence of infection 159 . Mice with genetic ablations of the recep tors for bacterial product ligands (TLR2, TLR4, TLR9 and NLP3) are protected from experimental liver fibrosis 159 . The current treatment philosophy involves decreasing the bacterial product ligands or blocking their receptors, which results in decreased inflamma tory and fibrogenic signalling in the liver, although no antifibrotic drug is currently available for routine clinical practice.
Hepatocellular carcinoma
The aetiology of non viral HCC follows a so called multiple hit pathway, whereby liver steatosis, followed by oxidative and ER stress, together with intestinal dysbiosis and inflammation, contributes to the final manifestation of cancer.
The gut microbiota dramatically changes in com position in hosts with HCC. Clostridium species have been found to be enriched in obesity induced mouse models of HCC 160, 161 , but clinical studies of patients with HCC detected an overgrowth of intestinal Escherichia coli 162 . Murine models and human studies have reported a migration of Helicobacter species to HCC tumour tissues [163] [164] [165] [166] . Notably, members of this genus are known to promote tumour development by activating NF κB and WNT signalling and suppressing antitumour immunity and might have a potential role in HCC development 163, 167 . To gain insights into the molecular events explain ing the progression of liver disease to HCC, various murine models (using diet, toxin plus diet and genetics plus diet) have been explored (TaBle 2) . However, most • ↓ Lactobacillus 133, 223 (humans and mice), Bacteroidetes (humans) 132, 134 and Akkermansia muciniphila (humans and mice) 58 • Gut microbiota protected against alcohol-induced liver injury 97 • Reduced fungal diversity ; Candida overgrowth 8 • ↑ Enterobacteriaceae (humans) 65, 224 , Lactobacillus (humans) 224, 225 , Bacteroides (humans and mice) 125, 161 and Ruminococcus (humans) 125 • ↓ Prevotella (humans) 125, 224 and Akkermansia muciniphila (mice) 59 • Gut microbiota mediated high-fat-diet-induced liver steatosis 226, 227 • Fungal dysbiosis not demonstrated
Reversibility of gut dysbiosis
Partial reversibility on abstinence 91, 113 Reversibility not demonstrated
• ↑ Systemic inflammatory markers (humans) 48, 228 • ↑ Intestinal TNF, IFNγ and IL-6 (humans and mice) 224, 229 • Systemic inflammatory markers (humans) 230 Transferability via the microbiome
• FMT from patients with alcoholic hepatitis caused severe liver inflammation and injury in mice 205 • FMT from ALD-resistant to ALD-susceptible mice prevented liver injury in recipient 131 • Co-housing inflammasome-deficient NASH mice with wild-type mice exacerbated liver steatosis in wild-type cage mates 49 • FMT from NAFLD-susceptible mice promoted liver injury in recipient 231 Translocation ↑ PAMPs translocation (endotoxins 48, [232] [233] [234] , β-glucan 8 and viral or bacterial DNA 232, 235 ) (humans and mice) ↑ PAMPs translocation (endotoxins 233, 236 , viral or bacterial DNA 237 ) (humans and mice)
Bile acids
• ↑ Total plasma bile acids (humans) 238 • ↑ Hepatic bile acid synthesis (humans and mice) 141, 142 • ↑ Total serum bile acids (humans) 239 • ↑ Hepatic bile acid synthesis (humans) 35 • ↑ Total faecal bile acids, primary to secondary bile acid ratio (humans) 35 
Choline
• ↓ Phosphatidylcholine in plasma and liver (rats) 240, 241 • Changes in trimethylamine not demonstrated • ↓ Phosphatidylcholine in plasma (mice) 242 • ↑ Intestinal trimethylamine (mice) 242 Free fatty acids • ↓ Bacterial fatty-acid biosynthesis (mice) 84 • LCFA and SCFA supplementation reduced ethanol-induced liver injury (mice) 84, 115 ↑ Free fatty acids in the liver 243 
Ethanol
• ↑ Blood ethanol and luminal acetaldehyde 130 • ↑ Systemic acetate 84, 242 ↑ Blood ethanol 65, 244, 245 ALD, alcoholic liver disease; FMT, faecal microbiota transplantation; LCFA , long-chain fatty acid; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PAMPs, pathogen-associated molecular patterns; SCFA , short-chain fatty acid.
of these models have proved suboptimal because they either do not develop all intermediate pathological and metabolic stages or they manifest HCC incompletely (M. Febbraio and M.K., unpublished observations). We have highlighted some frequently used rodent models of liver disease, their usage and caveats in TaBle 2 to aide future research. Accumulating evidence suggests that HCC associated dysbiosis is accompanied by gut barrier dys function, bacterial translocation, systemic circulation of their tumour promoting metabolites and activation of pro inflammatory and oncogenic signalling pathways 168 . The intestinal polymeric immunoglobulin receptor (PIGR) regulates the transport of IgA into the intestinal lumen and maintains microbial homeo stasis 169 . Pigr −/− mice modelling NASH induced HCC had increased levels of systemic and liver IgA and a concomitant increase in hepatic tumorigenesis owing to localized inhibition of liver cytotoxic T cells that prevent HCC development 170 . Furthermore, the application of broad spectrum antibiotics (such as ampicillin and amoxicillin) has been shown to attenuate liver inflammation and HCC development in mice 160, 171 , highlighting the role of the intestinal microbiome in liver tumorigenesis. In another mouse model in which HCC was induced by diethylnitrosamine (a carcinogen), activation of TLR4 due to lipopolysaccharide (LPS) translocation upreg ulated the hepatic mitogen proepiregulin (EREG) in hepatic stellate cells and activated NF κB, resulting in increased tumour cell proliferation 171 . Additionally, the secondary BA deoxycholic acid (increased in dietary or genetic obesity), a metabolic by product of gut bacteria, was shown to upregulate pro inflammatory genes, such as IL6 and TNF, to provoke a senescence associated secretory phenotype (SASP) in hepatic stel late cells, suggesting that SASP has a key role in at least obesity linked HCC development 160, [172] [173] [174] .
In addition to its role in HCC development, the gut microbiome also modulates pro tumorigenic adaptive immune response via T helper 17 (T H 17) cells, which produce the pro inflammatory cytokine IL17A [175] [176] [177] . The therapeutic efficacy of the anticancer drug cyclo phosphamide depended on the interplay between T H 17 signalling and the gut microbiome such that germ free tumour bearing mice or mice given non absorbable antibiotics had reduced T H 17 response, and a subsequent resistance to therapeutic effects of cyclophosphamide was seen 178 . Increased understanding of the role of the gut micro biota has motivated successful microbiome based therapeutic modalities for HCC, such as treatment with synthetic BAs to reduce HCC risk in patients with NAFLD 179 and non selective β blockers in the intesti nal mucosa (which prevent bacterial translocation and liver inflammation 180 ), and administration of probiotics in rodents models of HCC slowed tumour growth and reduced tumour size 181 .
Design of microbiome studies
Given the intense interest in the past decade in links between the microbiome and liver disease, we provide a brief overview of experimental models useful for researchers entering this field.
Association and case-control studies
Much of our knowledge of the human microbiome comes from association studies that use either a cross sectional or case control design. Well designed case control studies are critical to demonstrate a potential relation ship between microorganisms and a disease of interest. However, these studies cannot establish causality and are often subject to confounding variables such as differences in diet or medication between cases and controls. Most studies are conducted at a single time point in a popu lation with the disease, and no long term follow up is performed. Consequently, these studies can only iden tify microorganisms that differentiate individuals with the disease and the control population. Although these microorganisms identified might have been causative agents, it is nearly impossible to separate this association from secondary effects associated with the condition. For example, medication plays a major part in shaping the microbiome; a study of patients with type II diabetes mel litus found that treatment with metformin had a larger effect on the microbiome than the disease 182 . Similarly, we hypothesize the physiology of the disease might also contribute to changes in community structure.
Association studies are also often confounded by the selection of poor controls. The microbiome is dynamic 183, 184 , and cumulative exposures over an indi vidual's life, shaped by their diet 185 , lifestyle 186 , medical history 181, 182, 186, 187 , genetics 188 and other factors 189 , create a unique community. Thus, if cases and controls are not correctly selected, association studies might detect dif ferences owing to confounding factors. Matching cases and controls based on age and sex is often not sufficient. In cases in which this matching to control for confound ing variables is not possible, it is critically important to collect information about potential confounding factors.
Box 2 | Primary biliary cholangitis
Primary biliary cholangitis (PBC) is characterized by inflammation-mediated damage to the small bile ducts inside the liver and gradually progresses to liver fibrosis and cirrhosis 208 . The modified aetiological understanding of PBC, previously considered a typical autoimmune disorder, considers pro-inflammatory changes in the gut microbiota, intestinal bile acid disruptions and gut barrier dysfunction [208] [209] [210] [211] . Consequently, microbialassociated molecular patterns ascend the biliary duct, perpetuating infection. An immune attack against the biliary epithelial cells is mediated by antibodies that recognize the e2 subunit of the pyruvate dehydrogenase complex component e2 (PDCe2; also known as DlAT) owing to cross reactivity with conserved proteins in Escherichia coli 208 , Lactobacillus delbrueckii 212 and Novosphingobium aromaticivorans 213 . In fact, genetically susceptible mouse strains developed liver lesions mimicking PBC when infected with N. aromaticivorans, which further implicates a role for the microbiome in this disease 214 . ursodeoxycholic acid, a tertiary bile acid produced by Ruminococcus, has been approved for PBC treatment 215 . Thus, microbiome-based treatment modalities hold promise for managing PBC and should be studied further.
Comparisons across current cross sectional stud ies are also challenging owing to large effects caused by inter study differences in technical parameters, including sample collection, storage, primer selection and analy sis techniques 189 . Differences across stud ies increase the challenge of meta analysis and make identifying causative clades more difficult 190 . Some of these problems can be ameliorated by using consist ent methodology between studies 189, 190 . Efforts such as the Microbiome Quality Control Project are explor ing sources of technical variation 191 , whereas analysis platforms like Qiita provide a database of consistently annotated studies for comparison.
Twin studies
Twin studies provide a potential antidote to some of the problems with association studies. Twin pairs are naturally controlled for age and some early life exposures 192 . Monozygotic twin pairs also share the same genetic background, further limiting potential confounders 192 . Twin studies can be leveraged in two ways. First, identifying differences between discordant and concordant twin pairs represents more power ful association studies owing to the partial internal control. Although these studies are p articularly use ful in young children owing to shared environ ment, the approach can also be used with adults 193 . Second, twin studies are critical to examine genetic con trol of the microbiome. A study published in 2016 of the UK Twins cohort suggested strong association of the microbiome and genes, including those associated with dietary preference and serum lipids 194 . Twin stud ies provide a unique opportunity to assess whether the familial risk factors are either genetic or environmen tal in nature. These studies have been applied to study heritability for studying hepatic steatosis and fibrosis now that advanced MRI based assessment can be used to phenotype individuals 119, 195 . However, the sample size requirements for microbiome assessment in twins are large compared with the sample sizes needed to study heritability, making recruitment for such a study challenging 120, 194 . Twin studies might not be appropriate for other rare causes of liver diseases (for example, α1 antitrypsin deficiency, cirrhosis and PBC), and for low prevalence diseases, a trio family design would be more appropriate and would provide the highest power with the most efficient study design to detect association of a trait such as the role of microbiome on the risk of liver diseases 121 .
Longitudinal studies
As the cost of microbiome analysis decreases, longitudi nal studies are becoming more common. Understanding temporal fluctuation in the microbiome and the role of microorganisms in contributing to disease aetiology will rely on studies over time. Work suggests that commu nity instability might, in and of itself, be a characteris tic of an unhealthy ecosystem 196, 197 . Prospective studies, such as an investigation examining death from HCC in individuals with NAFLD, have helped identify the role of exposures and aetiological factors in contributing to disease outcomes 198 . Currently, the appropriate sampling frequency for understanding the microbiome in prospec tive studies is unknown, in part owing to an overall lack of long term follow up with microbiome studies. Initially, sample collection during standard clinic visits might pro vide information about the population scale changes in the microbiome population. However, incorporating microbiome samples into these long term studies will help examine the role of microbial communities -either at a single time point or the community dynamics -as a contributing factor to complex conditions 199 .
Animal models
Model animals also have an important role in shap ing our understanding of the microbiome in disease (TaBle 2) . Although rodent microbial communities are distinct from the human microbiota, there are some shared physiological and microbial traits 200 . Both rodent and human communities are dominated by the same set of bacterial phyla, although a smaller per centage of genera are shared 200 . As such, experimental findings implicating individual organisms or genera in rodents should be taken with caution until they are validated in humans. Instead, rodent models can show phenotypic consequences of microbiome manipulation. This aspect makes rodent models a useful model sys tem to investigate causality, explore interactions and test early interventions.
Both antibiotics and probiotics have been used to study the effect of changing the conventional mouse microbiome on a phenotypic outcome. Broad spectrum antibiotics decrease the total bacterial load and cause major perturbations in the microbial communities 201 . In some cases, such as in liver disease models, this approach can demonstrate the role of bacterial prod ucts, such as LPS, in modulating inflammation 127 . In other cases, such as a reported addiction model, this approach can be used to demonstrate the importance of an intact microbiome in regulating behaviour 202 . Probiotics can also be used to investigate the effect of a
Box 3 | Primary sclerosing cholangitis
Primary sclerosing cholangitis (PSC) is an immunemediated disease of the bile ducts 208 . However, unlike PBC, PSC can affect bile ducts both inside and outside of the liver. Gut dysbiosis-mediated bile dysregulation, intestinal permeability and translocation of proinflammatory molecules in the portal vein characterizes PSC 208, 216, 217 . The immune reaction in PSC is mediated by autoantibodies, including perinuclear antineutrophil cytoplasmic antibody, that recognize the ubiquitously expressed bacterial antigen cell division protein FtsZ 218 . Furthermore, increases in microorganism-associated Toll-like receptor expression and T helper 17 cells have been reported in PSC, which strongly suggests microbiome involvement in disease pathogenesis 219, 220 . PSC is closely associated with IBD 221 , particularly ulcerative colitis, and shares some of its characteristic features (such as increased levels of cells in the gut). Thus, a common disease mechanism might be in play, and novel treatment avenues by targeting microorganism-associated immune pathways can be explored. Diet affects the abundance of several taxa and is associated with changes in the microbiome 58 
Genetic manipulations
Knockout model A mouse line in which both copies of a gene have been removed
Pathology depends on the targeted gene. For example:
• Fxr −/− mice have more fatty liver accumulation on a high-fat diet 32 • Muc2 −/− mice are protected from diet-induced liver injury 107 • Gsta4 −/− ;Ppara −/− double-knockout mice have increased inflammation and fibrosis compared with either singlemutant or wild-type mice 250 The microbiome of lineage-derived mice is distinct from that of wild-type mice, which is likely to be an effect of microbiome drift within the colonies rather than a direct effect of the genotype . Gnotobiotic or germ free mice can be used in multi ple contexts. Comparisons of specific pathogen free lab oratory mice and germ free mice can be used to examine the role of the microbiome in modulating an expressed or induced phenotype 203, 204 . More importantly, gnoto biotic mice can be humanized with the stool of a donor. This approach creates a system in which an individual's microbiota can be tested either for its ability to modulate a disease phenotype or as a target for intervention 193, 203 . For instance, in a small study, mice received their micro biome from a donor with either severe alcoholic hepati tis or no liver disease. Following alcohol treatment, the mice with the microbiome from the patient with alco holic hepatitis showed greater liver damage than mice that received stool from the healthy donor 205 .
Well designed mouse models that combine our current understanding of liver disease with human ized microbiomes offer some of the greatest potential for preclinical interventions. Avatar mice, sometimes called patient derived xenograft (PDX) mice, are widely used in the cancer community to test the efficacy of chemotherapeutics for individual tumours, including HCC 206, 207 . This model better recapitulates the complex ity of a tumour than cell culture. Avatar mice can be further personalized by introducing a human immune system into an immunocompromised mouse along with the tumour 206 . Generating this model in germ free mice with a humanized microbiome and immune sys tem expands our capacity to understand the role of the microbiome in modulating cancer. For example, this model could be used to study whether the microbiome of a patient with ALD leads to more tumour growth than the microbiome from a healthy individual as control.
Conclusions
An accumulating body of research suggests that the disparate observations in liver diseaserelated studies are unified and explained by the microbiome. It is now widely accepted that liver damage can result from exten sive interplay between the gut microbiota via specialized molecules (such as TMA, acetaldehyde and LPS) and the host immune system via Kupffer cellmediated liver inflammation. However, a comprehensive understand ing of the interactions between the microbiome and the liver still evades us. Animal models, particularly rodents, have been instrumental in elucidating many important mechanistic pathways in liver disease aetiology. The introduction of the microbiome into these models will provide a more complete view of the cancer ecosystem. Because microbiome research is sensitive to technical variability that often masks underlying biological signals, there is a need for consistency in technical platforms and standardized protocols so that findings from different laboratories (and model organisms) can be replicated and validated. Additionally, it is critical to use an animal model that mimics human disease as closely as possible in all of its physiological and metabolic manifestations.
We are slowly advancing from observation based studies in humans as research establishes grounds for microbiome based therapeutic modalities such as FMT and probiotic interventions. However, effectively trans lating and applying findings accrued through animal models to humans requires well designed, large scale clinical trials spanning multiple disease aetiologies and patient characteristics. As the role of the microbiota in liver disease development, prognosis and treatment is increasingly recognized, we emphasize the need for focused, microbiome aware efforts to efficiently tackle the socioeconomic burden of this spectrum of liver diseases.
